然而,单用此疗法对实体瘤(如肝细胞癌)的疗效仍然有限,也还需要探索新的组合策略。 2023年,Cancer Communications期刊上发表了题为“Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatm...
这些基因可帮助 T 细胞识别并锁定淋巴瘤细胞表面上的一种蛋白。一旦这些CAR-T 细胞完全产生,它们就会被输注回患者体内。 在那项初始临床试验中,300 多名复发性或难治性大 B 细胞淋巴瘤患者接受了筛查,其中 269 人接受了 CAR-T 细胞疗法。总体而言,73%的患者出现了治疗反应,平均生存期延长至18个月。 在这项...
because of GVL. In this regard, donors’ immune cells recognize and attack to remaining leukemia as soon as injected, which does not happen in autologous HSCT [50,51]. Clinical investigations revealed a significant survival rate among AML patients after receiving alloHSCT. However, there are som...
Oncology Frontier-Hematology Frontier:The study findings indicate that CAR-T therapy is superior to teclistamab in terms of overall survival, with even more pronounced benefits observed in elderly patients and those who have ...
[1] .R. Westin, O.O. Oluwole, M.J. Kersten,et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. NEJM. 2023June 5; DOI: 10.1056/NEJMoa230 [2] Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 202...
Survival Gains Make CAR T-Cell Therapy Cost-Effective for Pediatric LeukemiaBecze, ElisaONS Voice
他们测量了无进展生存期(progression-free survival),即患者在治疗期间和治疗后患病但病情没有恶化的时间。该研究显示,在18.6个月的中位患者随访中,接受CAR-T细胞治疗的组别中,患者的无进展生存期为13.3个月,而标准治疗组只有4.4个月。Ailawadhi博士补充说,“这些发现表明,我们正朝着改变临床实践的研究方向前进,在...
瑞士医药巨头诺华(Novartis)宣布美国FDA(美国食品药品监督管理局)已批准其突破性CAR-T疗法Kymriah以治疗罹患急性淋巴性白血病(ALL)的病人。这是美国境内首个被批准的基因疗法,开启了基因治疗新篇章。 1. 基因治疗 美国时间周三一早,美国FDA(美国食品药品监督管理局)宣布批准了全美第一个基因治疗方法,来自于瑞士医药巨头...
Acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer and advances in treatment have improved outcomes. At St. Jude, the five-year ALL survival rate is 94%. However, patients with T-ALL who relapse have apoor prognosis, with a five-year survival rate of less than...
2017年7月12日,美国东部时间下午,经过了一天的详细讨论之后,由FDA召集的外部专家小组在星期三下午举行了投票,10:0,一致建议批准诺华公司的CAR-T新药CTL019(tisagenlecleucel-T)的生物制剂许可申请(BLA),用于治疗患有晚期白血病的儿童和年轻成人患者。这个投票是这一...